Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034
The 7 major Amyotrophic Lateral Sclerosis (ALS) markets reached a value of US$ 494.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 715.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.4% during 2024-2034.
Amyotrophic Lateral Sclerosis (ALS) market is currently driven by factors such as a rising geriatric population, a strong drug pipeline that have a good efficacy and safety profile and improving diagnosis and drug treatment rates. Amyotrophic lateral sclerosis is a rare neurological disorder that predominantly affects the nerve cells (neurons) responsible for controlling voluntary muscle movement. Although the indication can happen at any age, symptoms most commonly appear during the ages of 55 and 75. With the geriatric population expected to increase significantly over the long term, we expect the incidence of Amyotrophic Lateral Sclerosis to increase significantly over the next few years.
ALS belongs to a broader group of disorders known as motor neuron diseases, that are caused due to the gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend throughout the body from the brain to the spinal cord and to muscles. As motor neurons deteriorate, they cease sending messages to the muscles. As a result, the muscles gradually weaken, start to twitch, and waste away (atrophy). Eventually, this results in the brain losing its ability to initiate and control voluntary movements. Early symptoms of ALS normally include muscle weakness or stiffness. Gradually all voluntary muscles are affected, and patients lose their strength and the ability to speak, eat, move, and even breathe. The indication is progressive, resulting in the symptoms getting worse over time.
IMARC Group’s new report 'Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast' provides an exhaustive analysis of the Amyotrophic Lateral Sclerosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of the current and future landscape of the Amyotrophic Lateral Sclerosis market. This includes treatment practices, in-market, and pipeline drugs, the share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Amyotrophic Lateral Sclerosis across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Amyotrophic Lateral Sclerosis and represents the largest market for Amyotrophic Lateral Sclerosis treatment. Furthermore, the current Amyotrophic Lateral Sclerosis treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Amyotrophic Lateral Sclerosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current, and Future Epidemiology Scenario
Historical, Current, and Future Performance of the Amyotrophic Lateral Sclerosis Market
Historical, Current, and Future Performance of Various Therapeutic Categories in the Amyotrophic Lateral Sclerosis Market
Sales of Various Drugs Across the Amyotrophic Lateral Sclerosis Market
Reimbursement Scenario in the Amyotrophic Lateral Sclerosis Market
Competitive Landscape:
This report also provides a detailed analysis of the current Amyotrophic Lateral Sclerosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Amyotrophic Lateral Sclerosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Amyotrophic Lateral Sclerosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Amyotrophic Lateral Sclerosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Amyotrophic Lateral Sclerosis market?
Epidemiology Insights
What is the size of the Amyotrophic Lateral Sclerosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Amyotrophic Lateral Sclerosis across the seven major markets?
What are the key factors driving the epidemiological trend of Amyotrophic Lateral Sclerosis?
What will be the growth rate of Amyotrophic Lateral Sclerosis patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
What are the current marketed Amyotrophic Lateral Sclerosis drugs and what are their market performance?
What are the key pipeline Amyotrophic Lateral Sclerosis drugs and how are they expected to perform in the coming years?
How safe are the currently marketed Amyotrophic Lateral Sclerosis drugs and what are their efficacies?
How safe are the late-stage pipeline Amyotrophic Lateral Sclerosis drugs and what are their efficacies?
What are the current treatment guidelines for Amyotrophic Lateral Sclerosis drugs across the seven major markets?
Who are the key companies in the Amyotrophic Lateral Sclerosis market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Amyotrophic Lateral Sclerosis market?
Amyotrophic Lateral Sclerosis (ALS) market is currently driven by factors such as a rising geriatric population, a strong drug pipeline that have a good efficacy and safety profile and improving diagnosis and drug treatment rates. Amyotrophic lateral sclerosis is a rare neurological disorder that predominantly affects the nerve cells (neurons) responsible for controlling voluntary muscle movement. Although the indication can happen at any age, symptoms most commonly appear during the ages of 55 and 75. With the geriatric population expected to increase significantly over the long term, we expect the incidence of Amyotrophic Lateral Sclerosis to increase significantly over the next few years.
ALS belongs to a broader group of disorders known as motor neuron diseases, that are caused due to the gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend throughout the body from the brain to the spinal cord and to muscles. As motor neurons deteriorate, they cease sending messages to the muscles. As a result, the muscles gradually weaken, start to twitch, and waste away (atrophy). Eventually, this results in the brain losing its ability to initiate and control voluntary movements. Early symptoms of ALS normally include muscle weakness or stiffness. Gradually all voluntary muscles are affected, and patients lose their strength and the ability to speak, eat, move, and even breathe. The indication is progressive, resulting in the symptoms getting worse over time.
IMARC Group’s new report 'Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast' provides an exhaustive analysis of the Amyotrophic Lateral Sclerosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of the current and future landscape of the Amyotrophic Lateral Sclerosis market. This includes treatment practices, in-market, and pipeline drugs, the share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Amyotrophic Lateral Sclerosis across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Amyotrophic Lateral Sclerosis and represents the largest market for Amyotrophic Lateral Sclerosis treatment. Furthermore, the current Amyotrophic Lateral Sclerosis treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Amyotrophic Lateral Sclerosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current, and Future Epidemiology Scenario
Historical, Current, and Future Performance of the Amyotrophic Lateral Sclerosis Market
Historical, Current, and Future Performance of Various Therapeutic Categories in the Amyotrophic Lateral Sclerosis Market
Sales of Various Drugs Across the Amyotrophic Lateral Sclerosis Market
Reimbursement Scenario in the Amyotrophic Lateral Sclerosis Market
Competitive Landscape:
This report also provides a detailed analysis of the current Amyotrophic Lateral Sclerosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Amyotrophic Lateral Sclerosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Amyotrophic Lateral Sclerosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Amyotrophic Lateral Sclerosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Amyotrophic Lateral Sclerosis market?
Epidemiology Insights
What is the size of the Amyotrophic Lateral Sclerosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Amyotrophic Lateral Sclerosis across the seven major markets?
What are the key factors driving the epidemiological trend of Amyotrophic Lateral Sclerosis?
What will be the growth rate of Amyotrophic Lateral Sclerosis patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
What are the current marketed Amyotrophic Lateral Sclerosis drugs and what are their market performance?
What are the key pipeline Amyotrophic Lateral Sclerosis drugs and how are they expected to perform in the coming years?
How safe are the currently marketed Amyotrophic Lateral Sclerosis drugs and what are their efficacies?
How safe are the late-stage pipeline Amyotrophic Lateral Sclerosis drugs and what are their efficacies?
What are the current treatment guidelines for Amyotrophic Lateral Sclerosis drugs across the seven major markets?
Who are the key companies in the Amyotrophic Lateral Sclerosis market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Amyotrophic Lateral Sclerosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AMYOTROPHIC LATERAL SCLEROSIS - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 AMYOTROPHIC LATERAL SCLEROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AMYOTROPHIC LATERAL SCLEROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 AMYOTROPHIC LATERAL SCLEROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Amyotrophic Lateral Sclerosis Guidelines, Management and Treatment
8.2 Amyotrophic Lateral Sclerosis Treatment Algorithm
9 AMYOTROPHIC LATERAL SCLEROSIS - UNMET NEEDS
10 AMYOTROPHIC LATERAL SCLEROSIS - KEY ENDPOINTS OF TREATMENT
11 AMYOTROPHIC LATERAL SCLEROSIS - MARKETED PRODUCTS
11.1 List of Amyotrophic Lateral Sclerosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 AMYOTROPHIC LATERAL SCLEROSIS - PIPELINE DRUGS
12.1 List of Amyotrophic Lateral Sclerosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AMYOTROPHIC LATERAL SCLEROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 AMYOTROPHIC LATERAL SCLEROSIS - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Amyotrophic Lateral Sclerosis - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Amyotrophic Lateral Sclerosis - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Amyotrophic Lateral Sclerosis - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Amyotrophic Lateral Sclerosis - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Amyotrophic Lateral Sclerosis - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Amyotrophic Lateral Sclerosis - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Amyotrophic Lateral Sclerosis - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Amyotrophic Lateral Sclerosis - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
15 AMYOTROPHIC LATERAL SCLEROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 AMYOTROPHIC LATERAL SCLEROSIS MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AMYOTROPHIC LATERAL SCLEROSIS - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 AMYOTROPHIC LATERAL SCLEROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AMYOTROPHIC LATERAL SCLEROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 AMYOTROPHIC LATERAL SCLEROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Amyotrophic Lateral Sclerosis Guidelines, Management and Treatment
8.2 Amyotrophic Lateral Sclerosis Treatment Algorithm
9 AMYOTROPHIC LATERAL SCLEROSIS - UNMET NEEDS
10 AMYOTROPHIC LATERAL SCLEROSIS - KEY ENDPOINTS OF TREATMENT
11 AMYOTROPHIC LATERAL SCLEROSIS - MARKETED PRODUCTS
11.1 List of Amyotrophic Lateral Sclerosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 AMYOTROPHIC LATERAL SCLEROSIS - PIPELINE DRUGS
12.1 List of Amyotrophic Lateral Sclerosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AMYOTROPHIC LATERAL SCLEROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 AMYOTROPHIC LATERAL SCLEROSIS - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Amyotrophic Lateral Sclerosis - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Amyotrophic Lateral Sclerosis - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Amyotrophic Lateral Sclerosis - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Amyotrophic Lateral Sclerosis - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Amyotrophic Lateral Sclerosis - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Amyotrophic Lateral Sclerosis - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Amyotrophic Lateral Sclerosis - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Amyotrophic Lateral Sclerosis - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
15 AMYOTROPHIC LATERAL SCLEROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 AMYOTROPHIC LATERAL SCLEROSIS MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
